Virpax Pharmaceuticals said that it has acquired exclusive North American rights to Nanomerics’ MMS019 nasal powder, which it calls a “high density molecular masking spray” and which is intended to block viruses from taking hold in the respiratory tract. Virpax said that MMS019 is in preclinical development for the prevention of COVID-19, seasonal flu, and other respiratory viruses and that the company “intends to develop this product for potential FDA accelerated review in healthy human volunteers as soon as possible.”
Earlier this year, Virpax said that it had completed a pre-IND meeting with the FDA regarding its intranasal enkephalin for the treatment of management of acute and chronic pain, which it also licensed from Nanomerics.
Virpax Chairman and CEO Anthony Mack said, “We believe MMS019 can work together with current personal protective equipment to enhance our ability to help prevent the spread of respiratory viral infections and seasonal influenza.”
Nanomerics Chief Scientific Officer Ijeoma Uchegbu commented, “We are pleased that Virpax has licensed MMS019 for the prevention of viral respiratory infections and that they will undertake the clinical development of MMS019 to potentially bring a new respiratory infection prophylactic product to the market.”
Read the Virpax Pharmaceuticals press release.
